Aura Biosciences, Inc.
corporate_fare Company Profile
Aura Biosciences, Inc. (NASDAQ:AURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for AURA spans 10-Q, 8-K, S-3, DEF 14A.
Recent high-impact activity:
- Aura Q3 10-Q: $297.2M Cash Into 1H 2029, Net Loss Widens to $111.4M
- Aura Q3: CoMpass Treatment Complete, $297M Cash Into 1H 2029, CDMO Deal Signed
- Aura Biosciences Launches $500M Shelf and $200M ATM Program as It Restructures and Refocuses on Ocular Oncology
- Aura Biosciences Q2 2026: 20% Workforce Cut and Strategic Pivot to Ocular Oncology
- Aura Biosciences Q2 2026: Restructuring Sharpens Focus on Ocular Oncology, Cash Runway Extended into 1H 2029
Financial Snapshot
Short Interest & Short Volume
13.67 days to coverFINRA reported short interest of 10,464,215 shares in AURA as of the October 30, 2026 settlement, a 3.9% decrease from the prior period — about 13.7 days to cover at its recent average daily volume. On November 20, 2026, 72.6% of AURA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for AURA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-11.
New $500M Shelf Registration Filed · $200M ATM Program Established
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →